Ignite Creation Date:
2024-05-06 @ 5:37 PM
Last Modification Date:
2024-10-26 @ 2:32 PM
Study NCT ID:
NCT05377684
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2022-04-29
Brief Title:
Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment
Sponsor:
Ipsen
Organization:
Ipsen
Study Overview
Official Title:
Noninterventional Multicentre Prospective Cohort Study Assessing the Quality of Life and Hormonal Levels in Premenopausal Patients With Hormone Receptor-positive and HER2-negative Early Breast Cancer in Italy - ROSE Study
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ROSE
Brief Summary:
The main purpose of this study is to evaluate the quality of life of premenopausal participants with Hormone Receptor HR positive and Human Epidermal Growth Factor Receptor-2 HER2 negative breast cancer who are receiving in addition to triptorelin an endocrine cancer treatment The study will also get more information about - the effectiveness and safety of triptorelin - the relationship that could exist between the characteristics of the disease and the treatment chosen by the Investigator
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None